Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Jun;6(2):17-29.
doi: 10.1007/s40778-020-00170-6. Epub 2020 May 7.

Virus-specific T cells for malignancies - then, now and where to?

Sandhya Sharma  1   2 , Wingchi K Leung  1 , Helen E Heslop  1
Affiliations

Virus-specific T cells for malignancies - then, now and where to?

Sandhya Sharma et al. Curr Stem Cell Rep. 2020 Jun.

Abstract

Purpose of review: Virus-associated malignancies are a global health burden, constituting 10-12% of cancers worldwide. As these tumors express foreign viral antigens that can elicit specific T cell responses, virus-directed immunotherapies are a promising treatment strategy. Specifically, adoptive cell transfer of virus-specific T cells (VSTs) has demonstrated the potential to eradicate cancers associated with certain viruses.

Recent findings: Initial studies in 1990s first showed that VSTs specific for the Epstein-Barr virus (EBVSTs) can induce complete remissions in patients with post-transplant lymphoproliferative disease. Since then, studies have validated the specificity and safety of VSTs in multiple lymphomas and solid malignancies. However, challenges remain to optimize this platform for widespread use, including enhancing potency and persistence, overcoming the immunosuppressive tumor microenvironment, and streamlining manufacturing processes that comply with regulatory requirements.

Summary: This review focuses on data from clinical trials evaluating VSTs directed against three viruses (EBV, HPV and MCPyV), as well as recent preclinical and clinical advances, and potential future directions.

Keywords: Adoptive cell therapy; Hematological cancers; Oncovirus; Solid cancers; Virus associated malignancies; Virus specific T-cells.

PubMed Disclaimer

Conflict of interest statement

Disclosure of Potential Conflicts of Interest HEH has ownership interest (including stock, patents, etc.) in Allovir and Marker Therapeutics, and is a consultant/advisory board member for Novartis, Gilead Biosciences, Kiadis, Tessa Therapeutics, and PACT Pharma and has received commercial research grants from Cell Medica and Tessa Therapeutics. SS and WL have no potential conflicts of interest

Figures

Figure 1:
Figure 1:
Schematic illustration of different EBV latency stages characterized by limited gene expression in each latency stages and associated malignancies.
See this image and copyright information in PMC

References

    1. Chen Y, Williams V, Filippova M, Filippov V, Duerksen-Hughes P. Viral carcinogenesis: factors inducing DNA damage and virus integration. Cancers (Basel). 2014;6(4):2155–86. - PMC - PubMed
    1. Plummer M, de Martel C, Vignat J, Ferlay J, Bray F, Franceschi S. Global burden of cancers attributable to infections in 2012: a synthetic analysis. The Lancet Global Health. 2016;4(9):e609–e16. - PubMed
    1. Moore PS, Chang Y. Why do viruses cause cancer? Highlights of the first century of human tumour virology. Nat Rev Cancer. 2010;10(12):878–89. - PMC - PubMed
    1. Bouvard V, Baan R, Straif K, Grosse Y, Secretan B, Ghissassi FE, et al. A review of human carcinogens—Part B: biological agents. The Lancet Oncology. 2009;10(4):321–2. - PubMed
    1. Michaelis M, Doerr HW, Cinatl J. The story of human cytomegalovirus and cancer: increasing evidence and open questions. Neoplasia. 2009;11(1):1–9. - PMC - PubMed

LinkOut - more resources